Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Long-Term Deferred Tax of $2.4 million for Q1 2026, down 17.65% year-over-year from $3.0 million in Q1 2025, and down 2.82% quarter-over-quarter from $2.5 million in Q4 2025.
Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax fell 17.65% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 17.65% YoY), while the FY2025 annual figure was $2.5 million, down 11.9% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $2.4 million, down from $2.5 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $3.3 million in Q2 2024, with the low at $2.4 million in Q1 2026.
- The 4-year median for Long-Term Deferred Tax is $2.9 million (2024), against an average of $2.9 million.
- The sharpest annual moves came in 2024 and 2026: Long-Term Deferred Tax gained 5.4% in 2024, then dropped 17.65% in 2026.
- Protalix BioTherapeutics' Long-Term Deferred Tax stood at $3.1 million in 2023, then slipped by 7.63% to $2.9 million in 2024, then fell by 11.9% to $2.5 million in 2025, then fell by 2.82% to $2.4 million in 2026.
- Business Quant data shows PLX's Long-Term Deferred Tax at $2.4 million in Q1 2026, $2.5 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.37 Mn |
| Mar 31, 2026 | 2.45 Mn |
| Dec 31, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Mar 31, 2024 | 3.23 Mn |
| Dec 31, 2023 | 3.09 Mn |
| Sep 30, 2023 | 3.09 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Sep 30, 2018 | 1.45 Mn |
| Mar 31, 2014 | 135,000.00 |
| Dec 31, 2013 | 141,000.00 |
| Sep 30, 2013 | 149,000.00 |
| Sep 30, 2011 | 1.01 Mn |
| Jun 30, 2011 | 674,000.00 |